Myriad Genetics logo
Myriad Genetics MYGN
$ 4.78 -0.21%

Annual report 2025
added 02-24-2026

report update icon

Myriad Genetics Income Statement 2011-2026 | MYGN

Annual Income Statement Myriad Genetics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

409 M 973 M 1.8 B 1.75 B 2.21 B 1.49 B 2 B 2.97 B 1.62 B 2.17 B 2.4 B 2.78 B 2.43 B 2.19 B 1.91 B

Shares

92.6 M 90.6 M 82.8 M 81.2 M 80 M 75.4 M 73.5 M 69.4 M 68.3 M 70 M 71.3 M 75.7 M 80.9 M 84.6 M 89.8 M

Historical Prices

4.42 10.7 21.8 21.6 27.6 19.8 27.2 29.1 34.4 16.7 43.2 34.1 21 27.2 20.9

Net Income

-366 M -127 M -263 M -112 M -27.2 M -53.1 M 4.6 M 131 M 21.8 M 125 M 80.2 M 176 M 147 M 112 M 101 M

Revenue

824 M 838 M 753 M 678 M 691 M 300 M 851 M 773 M 771 M 754 M 723 M 778 M 613 M 496 M 402 M

Cost of Revenue

248 M 252 M 236 M 202 M - - - - 145 M 133 M 133 M 96.1 M 64.4 M 51.5 M 45.6 M

Gross Profit

577 M 585 M 517 M 476 M - - - 595 M 600 M 596 M 576 M 669 M 534 M 431 M 355 M

Operating Income

-387 M -124 M -257 M -141 M -190 M -87.8 M 7.6 M 122 M 44 M 153 M 134 M 274 M 228 M 180 M 158 M

Interest Expense

800 K 1.1 M -4.4 M 600 K 6.6 M 5.8 M 12 M 3.2 M 6 M 300 K 200 K -2 M -200 K -407 K 1.87 M

EBITDA

-334 M -62.3 M -196 M -87.9 M -128 M -52 M 80.6 M 112 M 97.7 M 194 M 159 M 288 M 237 M 189 M 165 M

Operating Expenses

964 M 709 M 774 M 617 M - - - 538 M 551 M 430 M 442 M 395 M 306 M 251 M 198 M

General and Administrative Expenses

257 M 276 M 284 M 248 M 538 M 260 M 556 M 467 M 476 M 359 M 366 M 327 M 252 M 208 M 170 M

All numbers in USD currency

Quarterly Income Statement Myriad Genetics

2025-Q3 2025-Q2 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

93.1 M 92.5 M 91.3 M 90.9 M 90.6 M 89.9 M 89.9 M 81.9 M 81.7 M 81.3 M 81.2 M 80.7 M 80.4 M 80.1 M 80 M 78.8 M 77.2 M 76 M 75.4 M 74.7 M 74.6 M 74.7 M 74.4 M 73.7 M 74.4 M 73.7 M 74.2 M 73 M 74.2 M 73 M 69.3 M 68.6 M 69.3 M 68.6 M 68.2 M 68.8 M 68.2 M 68.8 M 70.5 M 68.7 M 70.5 M 68.7 M 72.5 M 72.8 M 72.5 M 72.8 M 75.1 M 79.6 M 75.1 M 79.6 M 81.7 M 81.6 M 81.7 M 81.6 M 84.5 M 85.2 M 84.5 M 85.2 M

Net Income

-27.4 M -330 M - -22.1 M -36.7 M -26 M - -61.3 M -116 M -54.7 M - -35.1 M -14.1 M -20.5 M - 24.6 M -4.7 M -39.5 M -37.9 M -15.2 M -55.4 M -15.2 M -8.3 M -8.3 M -8.3 M -20.6 M 2.6 M 2.6 M 2.6 M -700 K 30.9 M 78.8 M 32.1 M 81.1 M 6.1 M -700 K 5.9 M -1.2 M 37.1 M 30.3 M 30.3 M 26.6 M 24 M 16 M 24 M 16 M 50.4 M 55.5 M 50.4 M 55.5 M 35 M 30.1 M 35 M 30.1 M 28.3 M 25.1 M 28.3 M 25.1 M

Revenue

206 M 213 M - 213 M 212 M 202 M - 192 M 184 M 181 M - 156 M 179 M 165 M - 167 M 189 M 173 M 155 M 145 M 93.2 M 145 M 195 M 186 M 195 M 186 M 217 M 202 M 217 M 194 M 194 M 190 M 384 M 197 M 196 M 178 M 196 M 178 M 193 M 184 M 193 M 184 M 184 M 169 M 184 M 169 M 204 M 202 M 204 M 202 M 149 M 133 M 149 M 133 M 123 M 110 M 123 M 110 M

Cost of Revenue

61.9 M 61.3 M - 63.5 M 64.4 M 64.6 M - 57.6 M 57.8 M 59.2 M - 50.4 M 49.7 M 48 M - - - - - - - - - - - - - - - 36.8 M 37.7 M 36.2 M 73.9 M 37.9 M 37.4 M 34.3 M 37.4 M 34.3 M 34.1 M 30.9 M 34.1 M 30.9 M 35.1 M 32.8 M 35 M 32.8 M 22.8 M 21.4 M 22.8 M 21.4 M 15.6 M 13.9 M 15.6 M 13.9 M 12.8 M 11.3 M 12.8 M 11.3 M

Gross Profit

144 M 152 M - 150 M 147 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-23.3 M -329 M - -20 M -36.5 M -27.9 M - -60.1 M -114 M -52.2 M - -45 M -17.8 M -25.6 M - -79.9 M -20.8 M -46.7 M -48.2 M -39.6 M -68.3 M -39.6 M -8.8 M -20.9 M -8.8 M -20.9 M 6.1 M 1.2 M 6.1 M 1.2 M 6.3 M 84 M 4.4 M 87.4 M 17.2 M 7.1 M 13.2 M 6.2 M 45.2 M 43.3 M 45.2 M 43.3 M 36.3 M 25.9 M 36.3 M 25.9 M 83 M 82.9 M 83 M 82.9 M 55.6 M 48.6 M 55.6 M 48.6 M 45.5 M 41.5 M 45.5 M 41.5 M

Interest Expense

400 K -100 K - -800 K -300 K 500 K - -700 K -2.4 M 500 K - 800 K 600 K 900 K - 1.1 M 2 M 3 M 2.9 M 2.9 M 3.1 M 2.9 M 2.5 M 2.9 M 2.5 M 2.9 M 3.4 M 2.2 M 3.4 M 2.2 M 700 K 900 K 700 K 900 K 2.6 M 700 K 2.6 M -2.5 M 100 K 100 K -300 K 100 K 1.5 M -100 K 1.51 M -98 K -185 K -439 K -185 K 923 K 14 K 1.24 M - - - - - 488 K

EBITDA

-18.5 M -324 M - -15.2 M -31.9 M -12.2 M - -56.7 M -111 M -32.8 M - -42.1 M -15 M -12.6 M - -30.4 M -3.9 M -28.3 M -48.2 M -21.9 M -50.6 M -21.9 M 9.4 M -2.7 M 27.6 M -2.7 M 24.1 M 19.5 M 24.1 M 19.5 M 19.4 M 97.2 M 17.5 M 101 M 30.1 M 16.3 M 26.2 M 15.4 M 52 M 50.1 M 52 M 50.1 M 42.3 M 31.9 M 42.4 M 31.9 M 85.4 M 85.3 M 85.4 M 85.3 M 57.8 M 50.8 M 60 M 48.9 M 45.7 M 43.6 M 49.9 M 43.6 M

Operating Expenses

167 M 481 M - 170 M 184 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

67.9 M 66.8 M - 69.2 M 72.1 M 141 M - 136 M 141 M 152 M - 130 M 127 M 111 M - 181 M 135 M 146 M 133 M 124 M 107 M 124 M 134 M 136 M 136 M 136 M 135 M 130 M 135 M 130 M 107 M 107 M 115 M 115 M 120 M 112 M 120 M 112 M 90.8 M 86.5 M 90.8 M 86.5 M 92.7 M 85.4 M 92.7 M 85.4 M 77.8 M 77.3 M 77.8 M 77.3 M 59.6 M 56.1 M 59.6 M 56.1 M 51 M 46.1 M 51 M 46.1 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Myriad Genetics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 0.65 -1.84 % $ 61.9 M irlandaIrlanda
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Agilent Technologies Agilent Technologies
A
$ 115.55 1.0 % $ 35.1 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 1.67 -2.34 % $ 2.22 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 24.46 3.25 % $ 679 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 21.23 5.83 % $ 1.13 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 84.33 1.82 % $ 5.69 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 16.31 1.75 % $ 493 M usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 410.54 4.35 % $ 11.8 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Charles River Laboratories International Charles River Laboratories International
CRL
$ 169.8 1.23 % $ 8.42 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Guardant Health Guardant Health
GH
$ 88.91 1.18 % $ 11.1 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.98 -2.37 % $ 8.76 M usaUSA
Illumina Illumina
ILMN
$ 127.88 1.95 % $ 20.3 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 17.23 -0.12 % $ 386 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 27.47 -0.58 % $ 20 B niderlandNiderland
Personalis Personalis
PSNL
$ 6.1 3.39 % $ 361 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Biomerica Biomerica
BMRA
$ 2.14 -0.47 % $ 4.92 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 102.17 -3.92 % $ 8.43 B irlandaIrlanda
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 263.8 -0.43 % $ 21.9 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Celcuity Celcuity
CELC
$ 121.03 6.58 % $ 5.66 B usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 469.71 0.64 % $ 177 B usaUSA
NeoGenomics NeoGenomics
NEO
$ 8.29 4.8 % $ 1.06 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 9.54 2.03 % $ 2.07 B usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 60.94 3.55 % $ 3.64 B usaUSA
Natera Natera
NTRA
$ 203.75 1.3 % $ 20.1 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 196.27 -1.66 % $ 21.8 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Waters Corporation Waters Corporation
WAT
$ 309.87 -0.43 % $ 18.5 B usaUSA